Valuation : Aligos Therapeutics, Inc.

Market Cap 3.66Cr 3.16Cr 2.97Cr 2.7Cr 5.09Cr 347.29Cr 5.11Cr 35Cr 14Cr 176.66Cr 14Cr 13Cr 585.77Cr P/E 2026 *
-0.9x
P/E 2027 * -1.12x
Enterprise Value 29.87L 25.77L 24.24L 22.08L 41.52L 28Cr 41.75L 2.87Cr 1.12Cr 14Cr 1.12Cr 1.1Cr 48Cr EV / Sales 2026 *
0.08x
EV / Sales 2027 * -48.2x
Free-Float
77.91%
Yield 2026 *
-
Yield 2027 * -
1 day+3.92%
1 week-12.12%
Current month+3.92%
1 month+43.97%
3 months+6.84%
6 months-13.37%
Current year-34.66%
1 week 5.61
Extreme 5.61
7.72
1 month 4.18
Extreme 4.18
7.82
Current year 3.98
Extreme 3.98
10.49
1 year 3.98
Extreme 3.98
13.69
3 years 3.76
Extreme 3.76
46.8
5 years 3.76
Extreme 3.76
449.25
10 years 3.76
Extreme 3.76
937.75
Manager TitleAgeSince
Chief Executive Officer 64 05/02/2018
Director of Finance/CFO 60 01/06/2020
Chief Tech/Sci/R&D Officer 65 01/05/2018
Director TitleAgeSince
Director/Board Member 64 01/08/2018
Director/Board Member 74 01/08/2018
Chairman 64 -
Date Insider Type Main position Quantity % Market Cap. Importance
09/03/26 Free

Chief Technology Officer

23,310 0.4354%
09/03/26 Free

Controller/Auditor

9,450 0.1765%
09/03/26 Free

Chief Executive Officer

1,05,840 1.9770%
Change 5-day change 1-year change 3-year change Capi.($)
+3.92%-12.12%-42.27%-71.71% 3.66Cr
+0.21%-1.70%+1.90%+18.18% 4.98TCr
+2.09%-0.81%+452.73%+517.81% 4.41TCr
-1.09%-0.73%+35.40%+16.04% 4.3TCr
-0.26%-3.58%+17.19%+72.80% 4.09TCr
-0.48%-3.09%+17.78%+49.80% 3.31TCr
-1.81%-5.94%+22.65%+115.79% 1.66TCr
-1.06%+3.29% - - 1.73TCr
-1.35%-2.32%+10.40%+25.90% 1.46TCr
-2.05%-5.44%+72.89%+36.51% 1.38TCr
Average -0.16%-3.02%+65.41%+86.79% 2.73TCr
Weighted average by Cap. -0.19%-1.79%+95.30%+124.42%

Financials

2026 *2027 *
Net sales 3.63Cr 3.13Cr 2.95Cr 2.69Cr 5.05Cr 344.83Cr 5.08Cr 35Cr 14Cr 175.41Cr 14Cr 13Cr 581.62Cr 54.25L 46.8L 44.02L 40.1L 75.41L 51Cr 75.82L 5.2Cr 2.03Cr 26Cr 2.04Cr 1.99Cr 87Cr
Net income -7.9Cr -6.81Cr -6.41Cr -5.84Cr -11Cr -749.53Cr -11Cr -76Cr -29Cr -381.27Cr -30Cr -29Cr -1.26TCr -12Cr -11Cr -10Cr -9.21Cr -17Cr -1.18TCr -17Cr -119.48Cr -47Cr -601.3Cr -47Cr -46Cr -1.99TCr
Net Debt -3.36Cr -2.9Cr -2.73Cr -2.48Cr -4.67Cr -318.94Cr -4.7Cr -32Cr -13Cr -162.24Cr -13Cr -12Cr -537.96Cr -30Cr -26Cr -24Cr -22Cr -41Cr -2.83TCr -42Cr -286.03Cr -111.33Cr -1.44TCr -111.95Cr -109.52Cr -4.77TCr
Logo Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.
Employees
82
Date Price Change Volume
02/26/02 $6.090 +3.92% 1,01,610
31/26/31 $5.860 -15.20% 98,916
28/26/28 $6.910 -2.26% 39,072
27/26/27 $7.070 -5.86% 80,522
26/26/26 $7.510 +0.54% 68,947
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.860USD
Average target price
56.29USD
Spread / Average Target
+860.51%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALGS Stock